Join us for an insightful morning on the European Health Technology Assessment Regulation (Regulation (EU) 2021/2282). The regulation is aiming to contributes to improving the availability for EU patients of innovative technologies in the area of health, such as medicines and certain medical devices. It aims at ensuring an efficient use of resources and strengthens the quality of Health Technology Assessment (HTA) across the EU. The Regulation provides a transparent and inclusive framework by establishing a Coordination Group of HTA national or regional authorities, a stakeholder network and by laying down rules on the involvement in joint clinical assessments and joint scientific consultations of patients, clinical experts, and other relevant experts.
In Denmark, it is the Danish Medicines Agency (DKMA) who is responsible for the Danish adaptation, and Head of Division, Kim Helleberg Madsen at the DKMA will provide his insights to the status of the regulation and the preparations for the implementation in Denmark.
